ULTIMOVACS ASA NON-REGULATORY PRESS RELEASEOslo ,April 9, 2024 :Ultimovacs ASA ("Ultimovacs ") (OSE ULTI),Ultimovacs ASA ("Ultimovacs ") (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company will host a webcast onApril 17, 2024 , at 11:00. Ultimovacs' management will provide a company update emphasizing recent developments and the future potential within the clinical program. The presentation will be followed by a Q&A session. Date:Wednesday, April 17, 2024 Time: 11:00 (CET) Link to webcast: https://channel.royalcast.com/landingpage/hegnarmedia/20240417_1/ (https://urldefense.proofpoint.com/v2/url?u=https- 3A__channel.royalcast.com_landingpage_hegnarmedia_20240417-5F1_&d=DwMFaQ&c=euGZs tcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=NB00oGVLQOaeHXBZQC-EDIkuh0a- ih3j5C_LRXMn- jk&m=C38XIprCpwdEkmQq6WKP2kMWhf_Di6Flp_x62NRiyg_w7bY7VPq72d4poyis6Qec&s=TRq- c8mhaADLV5C7EWjt2oqqHAQB4Ki9W63uwQ3Flmc&e=) The webcast can be accessed live or as a replay. Questions to the management can be sent in advance to ir@ultimovacs.com (mailto:ir@ultimovacs.com) or during the webcast. ==ENDS== About Ultimovacs Ultimovacs is a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines. The lead cancer vaccine candidate UV1 is an off-the-shelf vaccine directed against human telomerase (hTERT), an antigen present in 85-90% of cancers in all stages of tumor growth. A broad clinical program, with Phase II trials in five cancer indications enrolling more than 670 patients, aims to investigate UV1's impact in combination with other immunotherapies in multiple cancer types. UV1 is a patented technology owned byUltimovacs . In addition,Ultimovacs' adjuvant platform, based on the proprietary Tetanus-Epitope-Targeting (TET) technology, combines tumor-specific antigens and adjuvant in the same molecule and is in Phase I clinical development. The Company is listed onEuronext Oslo Stock Exchange (ULTI). About the UV1 Phase II program The immunotherapeutic cancer vaccine UV1 is investigated in combination with checkpoint inhibitors in patients with various cancer indications with diverse tumor biology. The clinical strategy behind the UV1 Phase II program's diversity is to evaluate the potential broad applicability of the cancer vaccine when combined with other immunotherapies: * INITIUM: Evaluating UV1 in combination with ipilimumab and nivolumab as first-line treatment for patients with malignant melanoma. Enrollment of 156 patients completed inJuly 2022 . Sponsored byUltimovacs . With the 18 months minimum follow-up of the patients in the INITIUM trial, the trial did not meet the primary or secondary endpoints. Median PFS was not reached in either arm. UV1 maintained its positive safety profile with similar safety and tolerability as observed in the control arm. *NIPU : Evaluating UV1 in combination with ipilimumab and nivolumab as second- line treatment for patients with malignant pleural mesothelioma. Enrollment of 118 patients completed inJanuary 2023 . Data presented at theESMO Congress inOctober 2023 , showed that UV1 as add-on to ipilimumab and nivolumab, demonstrated a statistically significant and clinically meaningful improvement of overall survival versus ipilimumab and nivolumab alone. 31% of the patients receiving UV1 vaccine experienced an objective response, compared to 16% in the control arm. The investigator-initiated study is led byOslo University Hospital and supported byBristol-Myers Squibb andUltimovacs . * FOCUS: Evaluating UV1 in combination with pembrolizumab as first-line treatment for patients with head and neck cancer. Enrollment of 75 patients completed in August 2023, expected readout Q3 2024. The investigator- initiated study is led byHalle University inGermany , supported byUltimovacs . * DOVACC: Evaluating UV1 in combination with olaparib and durvalumab as maintenance therapy in non-BRCA mutated patients with advanced ovarian cancer. 75 of 184 patients enrolled as of Q4 2023 reporting, expected readout H1 2025. The investigator-initiated study is led by NSGO-CTU and supported by ENGOT,AstraZeneca , andUltimovacs . * LUNGVAC: Evaluating UV1 combined with cemiplimab as first-line treatment of non-small cell lung cancer patients. 23 of 138 patients enrolled as of Q4 2023 reporting, expected readout H1 2026. The investigator-initiated study is led by Vestre Viken (Drammen Hospital ) and supported byUltimovacs . About UV1 UV1 is a universal cancer vaccine designed to induce a specific T-cell response against telomerase. UV1 consists of long, synthetic peptides representing a sequence in the reverse transcriptase subunit of telomerase (hTERT), shown to induce CD4+ T-cells. These CD4+ T-cells have the potential to provide inflammatory signals, and T-cell support is believed to be critical for triggering a strong anti-tumor immune response. Following intradermal injection, antigen-presenting cells (APCs) in the skin are exposed to the vaccine peptides. These APCs will process the peptides and present vaccine epitopes on Human Leukocyte Antigen (HLA) molecules to naïve T-cells in the lymph nodes. Activated vaccine-specific T-cells will then enter the circulation and search for cells displaying their cognate antigen in the context of HLA molecules. The UV1 peptides contain several epitopes, shown to be non-restrictive in terms of (HLA) alleles for presentation. It is, therefore not required to perform HLA pre-screening of patients, which potentially enables broad population utilization of the vaccine. UV1 is administered over three months as eight intradermal injections together with the immune-modulator GM-CSF. For further information, please contact:Carlos de Sousa , CEO Email: carlos.desousa@ultimovacs.com (mailto:carlos.desousa@ultimovacs.com) Phone: +47 908 92507Anne Worsøe , Head of Investor Relations Email: anne.worsoe@ultimovacs.com (mailto:anne.worsoe@ultimovacs.com) Phone: +47 90686815 This stock exchange announcement was published byAnne Worsøe , Head of Investor Relations atUltimovacs ASA , onApril 9, 2024 at20:00CET .
Click here for more information
© Oslo Bors ASA, source
